RecruitingNot applicableNCT04671771

A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease

Studying Complication in hemodialysis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
W.L.Gore & Associates
Principal Investigator
John Ross, MD
MUSC Health Dialysis Access Institute
Intervention
InnAVasc Arteriovenous Graft (IG) surgical implant(device)
Enrollment
133 target
Eligibility
18-90 years · All sexes
Timeline
20202029

Study locations (21)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04671771 on ClinicalTrials.gov

Other trials for Complication in hemodialysis

Additional recruiting or active studies for the same condition.

See all trials for Complication in hemodialysis

← Back to all trials